Inventor · disambiguated record
Matthew Koss
Also filed as: KOSS MATTHEW
8 granted patents·2 pending applications·18 citations·filing 2014–2024
82Inventor score
Files withREGENERON PHARMA10
Top patents by PatentIndex Score
10 records- 0196US11781131B2CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregationREGENERON PHARMA·Filed 2020·Granted Oct 10, 2023·5 cites·36 claims
- 0295US11845931B2CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregationREGENERON PHARMA·Filed 2020·Granted Dec 19, 2023·4 cites·37 claims
- 0393US12209238B2CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregationREGENERON PHARMA·Filed 2023·Granted Jan 28, 2025·1 cites·42 claims
- 0489US12110502B2Models of tauopathyREGENERON PHARMA·Filed 2023·Granted Oct 8, 2024·1 cites·42 claims
- 0589US11845957B2Models of tauopathyREGENERON PHARMA·Filed 2020·Granted Dec 19, 2023·2 cites·51 claims
- 0688US12421512B2CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregationREGENERON PHARMA·Filed 2024·Granted Sep 23, 2025·0 cites·32 claims
- 0782US12391920B2Models of tauopathyREGENERON PHARMA·Filed 2024·Granted Aug 19, 2025·0 cites·27 claims
- 0882US10023916B2Markers of tumor cell response to anti-cancer therapyREGENERON PHARMA·Filed 2014·Granted Jul 17, 2018·5 cites·3 claims
- 0976US2023416728A1Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregationREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1050US2018291468A1Markers of tumor cell response to anti-cancer therapyREGENERON PHARMA·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew Koss files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →